Bruker Corporation (BRKR) is a publicly traded Healthcare sector company. As of May 20, 2026, BRKR trades at $44.76 with a market cap of $6.51B and a P/E ratio of -182.83. BRKR moved +3.87% today. Year to date, BRKR is -13.64%; over the trailing twelve months it is +15.89%. Its 52-week range spans $28.53 to $72.94. Analyst consensus is buy with an average price target of $47.00. Rallies surfaces BRKR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded BRKR stock?
Recent politician trading activity in BRKR includes disclosures from Thomas R. Carper and Thomas R. Carper. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
BRKR Key Metrics
Key financial metrics for BRKR
Metric
Value
Price
$44.76
Market Cap
$6.51B
P/E Ratio
-182.83
EPS
$-0.24
Dividend Yield
0.05%
52-Week High
$72.94
52-Week Low
$28.53
Volume
1.62M
Avg Volume
0
Revenue (TTM)
$3.46B
Net Income
$-9.40M
Gross Margin
45.29%
Congressional Trades in BRKR
Thomas R. Carper sale (full) BRKR on Apr 17, 2023 (amount: $15.00K) for Spouse.
Thomas R. Carper purchase BRKR on Nov 20, 2020 (amount: $15.00K) for Spouse.
Recent politician trading activity in BRKR includes disclosures from Thomas R. Carper and Thomas R. Carper. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in BRKR?
Yes. Rallies tracks politician and congressional stock disclosures for BRKR, including reported purchases, sales, dates, owners, and trade amounts when available.
Is BRKR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BRKR. It does not provide personalized investment advice.
